{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10081","date":"2024-06-28T17:48:42.511Z","role":"Publisher"},{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10081","date":"2024-06-07T17:00:00.000Z","role":"Approver"}],"curationReasons":{"id":"cg:NewCuration"},"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/28513979","type":"dc:BibliographicResource","dc:abstract":"The cardinal features of Ectrodactyly, Ectodermal dysplasia, Cleft lip/palate (EEC), and Ankyloblepharon-Ectodermal defects-Cleft lip/palate (AEC) syndromes are ectodermal dysplasia (ED), orofacial clefting, and limb anomalies. EEC and AEC are caused by heterozygous mutations in the transcription factor p63 encoded by TP63. Here, we report a patient with an EEC/AEC syndrome-like phenotype, including ankyloblepharon, ED, cleft palate, ectrodactyly, syndactyly, additional hypogammaglobulinemia, and growth delay. Neither pathogenic mutations in TP63 nor CNVs at the TP63 locus were identified. Exome sequencing revealed de novo heterozygous variants in CHUK (conserved helix-loop-helix ubiquitous kinase), PTGER4, and IFIT2. While the variant in PTGER4 might contribute to the immunodeficiency and growth delay, the variant in CHUK appeared to be most relevant for the EEC/AEC-like phenotype. CHUK is a direct target gene of p63 and encodes a component of the IKK complex that plays a key role in NF-ÎºB pathway activation. The identified CHUK variant (g.101980394T>C; c.425A>G; p.His142Arg) is located in the kinase domain which is responsible for the phosphorylation activity of the protein. The variant may affect CHUK function and thus contribute to the disease phenotype in three ways: (1) the variant exhibits a dominant negative effect and results in an inactive IKK complex that affects the canonical NF-ÎºB pathway; (2) it affects the feedback loop of the canonical and non-canonical NF-ÎºB pathways that are CHUK kinase activity-dependent; and (3) it disrupts NF-ÎºB independent epidermal development that is often p63-dependent. Therefore, we propose that the heterozygous CHUK variant is highly likely to be causative to the EEC/AEC-like and additional hypogammaglobulinemia phenotypes in the patient presented here.","dc:creator":"Khandelwal KD","dc:date":"2017","dc:title":"Identification of a de novo variant in CHUK in a patient with an EEC/AEC syndrome-like phenotype and hypogammaglobulinemia."},"evidence":[{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":3.6},{"id":"cggv:85c45b5d-00a2-4c01-9859-c51c63b3f147_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:85c45b5d-00a2-4c01-9859-c51c63b3f147","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":{"id":"cggv:16afd6e2-ffef-4ccc-9bba-4d4651a22b7e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001278.5(CHUK):c.1739A>G (p.Tyr580Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378148833"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0006532","obo:HP_0001508","obo:HP_0002110","obo:HP_0001399","obo:HP_0011842","obo:HP_0010976","obo:HP_0004313","obo:HP_0001581","obo:HP_0002028"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:1939119a-2da4-4079-b801-e5ef31d3d073_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:16afd6e2-ffef-4ccc-9bba-4d4651a22b7e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/34533979","type":"dc:BibliographicResource","dc:abstract":"Inhibitor of nuclear factor kappa B kinase alpha (IKKÎ±) is critical for p100/NF-ÎºB2 phosphorylation and processing into p52 and activation of the noncanonical NF-ÎºB pathway. A patient with recurrent infections, skeletal abnormalities, absent secondary lymphoid structures, reduced B cell numbers, hypogammaglobulinemia, and lymphocytic infiltration of intestine and liver was found to have a homozygous p.Y580C mutation in the helix-loop-helix domain of IKKÎ±. The mutation preserves IKKÎ± kinase activity but abolishes the interaction of IKKÎ± with its activator NF-ÎºBâ€“inducing kinase and impairs lymphotoxin-Î²â€“driven p100/NF-ÎºB2 processing and ","dc:creator":"Bainter W","dc:date":"2021","dc:title":"Combined immunodeficiency with autoimmunity caused by a homozygous missense mutation in inhibitor of nuclear factor ð›‹B kinase alpha (IKKÎ±)."}},"rdfs:label":"Bainter Proband 1"},{"id":"cggv:1939119a-2da4-4079-b801-e5ef31d3d073","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:1939119a-2da4-4079-b801-e5ef31d3d073_variant_evidence_item"},{"id":"cggv:1939119a-2da4-4079-b801-e5ef31d3d073_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"No","dc:description":"The Y580C mutation did not affect IKKÎ± protein expression in the patient fibroblasts. An in vitro kinase assay, using purified recombinant wild-type (WT) or mutant IKKÎ±Y580C and IÎºBÎ±21â€“41 peptide as substrate, revealed that the intrinsic kinase activity of the mutant was intact. This functional data does not showcase a deleterious impact of the variant."}],"strengthScore":0.05,"dc:description":"Down scored due to parental consanguinity "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:36354305-1e18-476b-9a2b-afa21d452856_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:36354305-1e18-476b-9a2b-afa21d452856","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":5,"allele":[{"id":"cggv:35eb7cce-55eb-4691-a93b-5dc29550924c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001278.5(CHUK):c.569C>T (p.Pro190Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378154918"}},{"id":"cggv:f9ea9e4f-1e46-490d-a9e9-cc4f63da7efe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001278.5(CHUK):c.425A>G (p.His142Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378155510"}}],"detectionMethod":"Sequenced the CHUK cDNA from fibroblasts and peripheral blood mononuclear cells (PBMCs), which was confirmed using Sanger sequencing. ","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000403","obo:HP_0000581","obo:HP_0006532","obo:HP_0000201","obo:HP_0004313","obo:HP_0001596","obo:HP_0002608","obo:HP_0000968"],"previousTesting":true,"previousTestingDescription":"Trio whole exome sequencing was performed, which identified one de novo pathogenic variant in CHUK c.425A>G (p.His142Arg).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"cggv:770f21f4-25d1-46d3-b6ae-dfdfde00e34d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f9ea9e4f-1e46-490d-a9e9-cc4f63da7efe"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/38798321","type":"dc:BibliographicResource","dc:abstract":"IKKÎ±, encoded by ","dc:creator":"Riller Q","dc:date":"2024","dc:title":"Compound heterozygous mutations in the kinase domain of IKKÎ± lead to immunodeficiency and immune dysregulation."}},{"id":"cggv:06b7f9f6-9215-4162-8e8e-b13e7e8af85b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:35eb7cce-55eb-4691-a93b-5dc29550924c"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/38798321"}],"rdfs:label":"Riller Proband 1"},{"id":"cggv:06b7f9f6-9215-4162-8e8e-b13e7e8af85b","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:06b7f9f6-9215-4162-8e8e-b13e7e8af85b_variant_evidence_item"},{"id":"cggv:06b7f9f6-9215-4162-8e8e-b13e7e8af85b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"No quantitative difference was found by RTqPCR of CHUK mRNA in fibroblasts. Total IKKÎ± protein expression was lower in SV40-fibroblasts than in the controls suggesting a potential instability of the mutated proteins. Transfection experiments of these variants or the WT in HEK293T cells showed a slightly decreased expression for both variants as compared to the wild-type thereby confirming that the IKKÎ± p.H142R and p.P190L mutants could be less stable than the wild-type IKKÎ±. "}],"strengthScore":0.5},{"id":"cggv:770f21f4-25d1-46d3-b6ae-dfdfde00e34d","type":"obo:SEPIO_0004097","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:770f21f4-25d1-46d3-b6ae-dfdfde00e34d_variant_evidence_item"},{"id":"cggv:770f21f4-25d1-46d3-b6ae-dfdfde00e34d_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"No quantitative difference was found by RTqPCR of CHUK mRNA in fibroblasts. Total IKKÎ± protein expression was lower in SV40-fibroblasts than in the controls suggesting a potential instability of the mutated proteins. Transfection experiments of these variants or the WT in HEK293T cells showed a slightly decreased expression for both variants as compared to the wild-type thereby confirming that the IKKÎ± p.H142R and p.P190L mutants could be less stable than the wild-type IKKÎ±"}],"strengthScore":1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8331cc3b-6984-4dbe-b6a6-e3bf3ccb9112_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8331cc3b-6984-4dbe-b6a6-e3bf3ccb9112","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":[{"id":"cggv:9c9c27fd-73cc-4b96-aa07-8acd1259eb9e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001278.5(CHUK):c.1365del (p.Arg457AspfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695212594"}},{"id":"cggv:b4433044-8b79-40fe-9c12-ae9158e6788a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001278.5(CHUK):c.1388C>A (p.Thr463Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA378151492"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000403","obo:HP_0000175","obo:HP_0000966","obo:HP_0009755","obo:HP_0000685","obo:HP_0200117","obo:HP_0410030","obo:HP_0010701"],"previousTesting":true,"previousTestingDescription":"CMA which revealed a 2 MB deletion on chromosome 1 encompassing 18 genes (arr [hg19] 1q21.1q21.2 (145,885,645â€“147,929,115)). Parental studies were requested but not performed.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"cggv:4c491ae1-e91c-481f-aae0-e73f881125e1_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9c9c27fd-73cc-4b96-aa07-8acd1259eb9e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29523099","type":"dc:BibliographicResource","dc:abstract":"Ectodermal dysplasias (ED) are a group of diseases that affects the development or function of the teeth, hair, nails and exocrine and sebaceous glands. One type of ED, ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC or Hay-Wells syndrome), is an autosomal dominant disease characterized by the presence of skin erosions affecting the palms, soles and scalp. Other clinical manifestations include ankyloblepharon filiforme adnatum, cleft lip, cleft palate, craniofacial abnormalities and ectodermal defects such as sparse wiry hair, nail changes, dental changes, and subjective hypohydrosis.","dc:creator":"Cadieux-Dion M","dc:date":"2018","dc:title":"Novel heterozygous pathogenic variants in CHUK in a patient with AEC-like phenotype, immune deficiencies and 1q21.1 microdeletion syndrome: a case report."}},{"id":"cggv:d595ce19-fe6f-4390-91b0-4f0dd51d70aa_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b4433044-8b79-40fe-9c12-ae9158e6788a"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29523099"}],"rdfs:label":"Cadieux-Dion Proband 1"},{"id":"cggv:d595ce19-fe6f-4390-91b0-4f0dd51d70aa","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d595ce19-fe6f-4390-91b0-4f0dd51d70aa_variant_evidence_item"}],"strengthScore":0.5},{"id":"cggv:4c491ae1-e91c-481f-aae0-e73f881125e1","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:4c491ae1-e91c-481f-aae0-e73f881125e1_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.6},{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:9c06ebf7-9fa8-4440-8141-b6601bb5bb81","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:bd56ea20-f56f-4032-90be-333adc4eccd5","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"Activation of the noncanonical NF-ÎºB pathway leads to NF-ÎºB-inducing kinase (NIK) activation and subsequent phosphorylation of IKKÎ±. Human embryonic kidney (HEK) 293T cells were cotransfected with HA-tagged WT or mutant IKKÎ± and Myc-tagged NIK followed by immunoprecipitation with anti-HA. Myc-NIK coimmunoprecipitated with HA-tagged WT IKKÎ± but not HA-tagged mutant IKKÎ±. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34533979","rdfs:label":"HEK 293T mutant transfection and CoIP"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5,"dc:description":"This experiment demonstrates that the Y580C IKKÎ± mutation disrupts NIK binding and thereby selectively impairs noncanonical NF-ÎºB signaling."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:6b115147-70e4-4456-8d78-20a40909c78a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:3ad00d1d-5402-4651-bb04-3c3908c2afc6","type":"FunctionalAlteration","dc:description":"To go deeper in the characterization of the canonical NF-ÎºB pathway, we performed a bulk RNA sequencing of SV40-fibroblasts from the patient and controls before and after 6 hours of stimulation with TNFÎ± or Poly I:C (TLR3 agonist) two potent activators of the canonical NF-ÎºB pathway. They also included NEMOY/- SV40-fibroblasts (NEMO null), known to be unresponsive to TNFÎ± stimulation, as well as the SV40-fibroblasts from a patient carrying the heterozygous NFKB2 p.R853* variant. Upon TNFÎ± stimulation, TNFÎ± induced-genes or genes from the TNFÎ± signaling via NF-ÎºB signature were significantly less upregulated in fibroblasts from the patient than in fibroblasts from controls. Accordingly, pathway activity inference based on previous knowledge (PROGENy) showed a profound defect in the activation of the TNFÎ± signaling. This was confirmed by Ingenuity Pathway Analysis (QIAGEN) showing that TNFÎ±, IL1Î² and lipopolysaccharide (LPS), 3 potent activators of the canonical NF-ÎºB pathway, were in the top 3 molecules predicted to be inhibited based on the differentially expressed genes (DEGs) between the patientâ€™ cells and control cells. In contrast to the IKKa patientâ€™ cells, the NFKB2 p.R853* patientâ€™s cells were in the range of controls both after TNFÎ± and TLR3 stimulation for NF-ÎºB target genes while NEMO null cells were unable or less able to upregulate genes upon TNFÎ± and TLR3 stimulation, as previously reported.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38798321","rdfs:label":"Riller canonical NF-ÎºB pathway experiment"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"cggv:ed26c19c-5dd4-4ac2-b02a-cb2265a52c3d","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:54fba97c-05de-4f60-aa2f-130584277f82","type":"FunctionalAlteration","dc:description":"Activation of the noncanonical NF-ÎºB pathway was severely impaired in the patient skin-derived fibroblasts, as evidenced by lack of p100 processing after cross-linking of LTÎ²R with agonistic anti-LTÎ²R monoclonal antibody (mAb). The patientâ€™s fibroblasts failed to up-regulateÂ VCAM1Â after LTÎ²R ligation, but demonstrated intactÂ VCAM1Â up-regulation after TNF-Î± stimulation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34533979","rdfs:label":"Patient fibroblast experiments"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1,"dc:description":"This experiment shows that the IKKÎ± Y580C impairs the normal functioning of the protein and its ability to activate noncanonical NF-ÎºB signaling."}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:6b6c3bfe-95ff-4ade-bbb3-6e81ac86e1ac","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:d51c64d4-e17c-4828-b56c-a070127aa460","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"With the patient cells alone, they still observed the impaired cleavage of p100 to p52 as well as the impaired RELB nuclear translocation after 24 or 48h of LTÎ±1Î²2 or Tweak stimulation in the cells transduced with the empty lentivirus. In contrast, transduction of the wt IKKÎ± rescued the p100 cleavage as well as the nuclear translocation of RELB as compared to healthy control SV40-fibroblasts.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38798321","rdfs:label":"Riller fibroblast rescue experiment "}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1},{"id":"cggv:1fd5b6f2-5dd0-498e-9498-85b849182361","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:ef9b952e-4c58-4980-8222-a387f267bde1","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"B cell development in the bone marrow was normal in IKKÎ±Y580C/Y580C mice. The proportions of recirculating mature B cells were reduced in the mutantsâ€™ bone marrow, and the mutants had diminished splenic B cell numbers. They also demonstrated a partial, yet significant, block between the transitional 1 (T1) and T2 stages of development. B220hiIgM+ B-2 cells were markedly diminished in the peritoneum of mutant mice compared with WT controls. B220intIgM+ B-1 cells were increased ~2-fold in the mutant but secreted about half the amount of IgM compared with WT controls. IKKÎ±Y580C/Y580C mice had a severe reduction in serum IgG and IgA levels but normal serum IgM levels. After intraperitoneal immunization with TNP-KLH, spleens from the mutant mice had significantly reduced numbers of CD4+CXCR5+PD1+ T follicular helper (TFH) cells compared with WT controls, and they virtually lacked B220+CXCR5+GL7+ germinal center (GC) B cells. T cells from IKKÎ±Y580C/Y580C mice have impaired IL-2 and IL-17A production in vitro and fail to respond to cutaneous immunization with antigen. There was reduced cutaneous Il17a expression and susceptibility to S. aureus skin infection in IKKÎ±Y580C/Y580C mice. Developmental and functional defects in the thymus of IKKÎ±Y580C/Y580C mice enable expansion of potentially autoreactive T cell clones. The organs of IKKÎ±Y580C/Y580C mice are infiltrated by activated T cells and show evidence of tissue damage.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34533979","rdfs:label":"Bainter Mouse Model Experiments"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2,"dc:description":"The mouse model created was able to showcase phenotypes of the proband that were documented. Furthermore, the authors showed evidence of impairment in both B cells and T cells from the Y580C variant as well as defects in the thymus and ability to respond to immunizations as well as recurrent infections. "}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5.5}],"evidenceStrength":"Moderate","sequence":8529,"specifiedBy":"GeneValidityCriteria10","strengthScore":9.1,"subject":{"id":"cggv:d6d309e3-fb66-4d98-b073-bf87d0ee7ab1","type":"GeneValidityProposition","disease":"obo:MONDO_0859154","gene":"hgnc:1974","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"CHUK was first reported in relation to autosomal recessive inheritance in Cocoon syndrome in 2010 (Lahtela et al ., PMID: 20961246) and Popliteal pteryium syndrome, Bartoscas-Papas type 2 in 2015 (Leslie et al., PMID: 25691407). The first reporting of a CHUK variant with symptoms of hypogammaglobinemia was in 2017 (Khandelwal et al., PMID:28513979) however only one pathogenic variant was found. The second pathogenic variant was identified in the proband documented in a current pre-print article by Riller et al., (PMID: 38798321). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanisms and inheritance pattern; therefore, the following disease entities have been lumped into one disease entities, Cocoon syndrome (OMIM:Â 613630) and Popliteal pterygium syndrome, Bartoscas-Papas type 2 (OMIM: 619339).Â \u000b\nSix variants (missense and frameshift) that have been reported in three probands in three publications (PMIDs: 29523099, 34533979, 38798321 - pre-print) are included in this curation. These probands have recurrent upper and lower respiratory infections and hypogammaglobulinemia as well as abnormal skeletal morphology. There are no documented phenotypes reported in carriers of these variants. The mechanism of pathogenicity appears to be loss of functionÂ \n\nThis gene-disease relationship is also supported by experimental evidence (animal models, expression studies, rescue, and in vitro functional assays,) (PMIDs: 29523099, 34533979, 38798321-pre-print). Expression studies and in vitro functional assays show that non-canonical NF-kB signaling is impaired through the disruption of NIK binding and lack of p100 processing. Expression studies from the pre-print, Riller et al., (2024) showcases that introduction of wildtype CHUK sequence is able to rescue p100 processing and increase nuclear translocation of RELB in transduced fibroblasts (PMID:38798321-pre-print). Animal models are able to capture proband phenotypes and showcase reduced mature B cells, a severe reduction in serum IgG and IgA levels, a reduction in memory and effector T cells, inability to respond to immunization, and recurrent infections. Â \u000b\nIn summary, there is moderate evidence supporting the relationship between CHUK and autosomal recessive Popliteal pteryium syndrome, Bartoscas-Papas type 2. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen SCID-CID GCEP on the meeting date June 7th, 2024 (SOP Version 10).Â \n","dc:isVersionOf":{"id":"cggv:c75e589b-683e-4b4f-b2f5-59e1eadf42d1"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}